2025
Epigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge
Qin T, Mattox A, Campbell J, Park J, Shin K, Li S, Sadow P, Faquin W, Micevic G, Daniels A, Haddad R, Garris C, Pittet M, Mempel T, ONeill A, Sartor M, Pai S. Epigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge. Journal Of Clinical Investigation 2025, 135: e181671. PMID: 40091844, PMCID: PMC11910227, DOI: 10.1172/jci181671.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsAzacitidineB7-H1 AntigenEpigenesis, GeneticFemaleHead and Neck NeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapyMaleMiddle AgedProgrammed Cell Death 1 ReceptorSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentConceptsHead and neck squamous cell carcinomaTumor microenvironmentProlonged OSOverall survivalIFN-gCD8+ T cell infiltrationCD4+ T regulatory cellsOn-treatment tumor biopsiesNeck squamous cell carcinomaSystemic host immune responseBackgroundImmune checkpoint blockadeMetastatic (R/MMedian overall survivalPD-L1 expressionT cell infiltrationLocal tumor microenvironmentT regulatory cellsSquamous cell carcinomaBiologically Effective DosePhase 1b clinical trialHost immune responseCheckpoint blockadeOS ratesPD-L1Tumor biopsies
2024
Association of Biologically Effective Dose and Survival in Patients Receiving Head and Neck Stereotactic Body Radiation Therapy
Márquez C, Phan J, Lee A, Reddy J, Garden A, Gunn G, Frank S, Fuller C, Moreno A, Morrison W, Rosenthal D, Spiotto M. Association of Biologically Effective Dose and Survival in Patients Receiving Head and Neck Stereotactic Body Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e770-e771. DOI: 10.1016/j.ijrobp.2024.07.1694.Peer-Reviewed Original ResearchStereotactic body radiation therapyHead and neck cancerBiologically Effective DoseRadiation therapyPerformance statusN stagePatients treated with stereotactic body radiation therapyTreat recurrent head and neck cancerPatients treated with initial surgeryRecurrent head and neck cancerHigher biologically effective dosesIncreasing BEDMedian follow-up durationAssociated with improved survivalHead and neck cancer patientsEffective doseNo survival improvementSurgically resected patientsNational Cancer DatabaseFractionation schemeAssociated with enhanced survivalCox regression modelsDose escalationHPV statusResected patientsRadioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy
Verma N, Laird J, Moore N, Hayman T, Housri N, Peters G, Knowlton C, Jairam V, Campbell A, Park H. Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy. Advances In Radiation Oncology 2024, 9: 101500. PMID: 38699671, PMCID: PMC11063223, DOI: 10.1016/j.adro.2024.101500.Peer-Reviewed Original ResearchLocal recurrence-free survivalNon-lung primaryAssociated with higher local recurrence-free survivalProgression-free survivalBiologically Effective DoseLocal controlRadioresistant metastasesOverall survivalPulmonary metastasesPrimary cancerColorectal carcinomaAssociated with superior local controlMultivariate analysisPatients treated with radiotherapyRisk of local recurrenceMedian follow-up timeMultivariable Cox proportional hazards regressionInferior local controlMedian total doseSuperior local controlAssociated with decreased riskImpact of histologyMetastasis-free survivalRecurrence-free survivalLocal failure
2017
HDR Monotherapy in Prostate Cancer: Radiobiological Considerations When Determining Biologically Effective Dose in Clinical Trials
Tien C, Carlson D, Nath R, Chen Z. HDR Monotherapy in Prostate Cancer: Radiobiological Considerations When Determining Biologically Effective Dose in Clinical Trials. Brachytherapy 2017, 16: s31. DOI: 10.1016/j.brachy.2017.04.038.Peer-Reviewed Original Research
2016
A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy
Stahl J, Ross R, Harder E, Mancini B, Soulos P, Dosoretz A, Finkelstein S, Shafman T, Husain Z, Evans S, Yu J, Gross C, Decker R. A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s174-s175. DOI: 10.1016/j.ijrobp.2016.06.438.Peer-Reviewed Original Research
2012
On the Use of Biologically Effective Dose (BED) and Iso-Effective Dose (IED) in Radiobiological Evaluations of Permanent Brachytherapy With Proliferating Tumors
Chen Z, Nath R. On the Use of Biologically Effective Dose (BED) and Iso-Effective Dose (IED) in Radiobiological Evaluations of Permanent Brachytherapy With Proliferating Tumors. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s755. DOI: 10.1016/j.ijrobp.2012.07.2020.Peer-Reviewed Original ResearchBiologically Effective DoseIso-effective doseProliferating tumorsPermanent brachytherapyRadiobiological evaluationEffective doseDose
2007
TH‐E‐M100E‐07: The Impact of Procedure‐Induced Edema On Cell Survival and Tumor Control Probability in Permanent Prostate Brachytherapy Using 131Cs Radioactive Source
Chen Z, Deng J, Roberts K, Nath R. TH‐E‐M100E‐07: The Impact of Procedure‐Induced Edema On Cell Survival and Tumor Control Probability in Permanent Prostate Brachytherapy Using 131Cs Radioactive Source. Medical Physics 2007, 34: 2655-2655. DOI: 10.1118/1.2761777.Peer-Reviewed Original ResearchTumor control probabilityBiologically Effective DoseControl probabilityPermanent prostate brachytherapyRadioactive sourcesConcept of biologically effective doseProstate brachytherapyProstate edemaEdema magnitudeProtracted dose deliveryPotential doubling timeRepair half-timeCell survivalDose deliveryEffectiveness of cell killingCell killingTumor potential doubling timeSurviving fraction of cancer cellsEdema-induced increaseInitial tumor burdenFraction of cancer cellsRadiation-induced cell killingHalf-lifeDoubling timeTumor burden
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply